155 completed, 19 terminated, 14 recruiting, 13 unknown. 94 Phase 3, 45 Phase 2, 37 Phase 4, 20 Phase 1, 2 Early Phase 1.
Follow secukinumab: new trials by email Literature Review of secukinumab trials Research Report on secukinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis Secukinumab (IL-17i ), Upadacitinib (JAKi) - Axial Spondyloarthritis (AxSpA) | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 40 | 2026-11-01 | 2026-10-14 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease Secukinumab (75 mg), Standard Medical Therapy - Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease | Phase 4 | Not yet recruiting | Peking University Third Hospital | 100 | 2026-07-15 | 2026-07-15 |
| Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients Secukinumab 300mg s.c., Metformin, Placebo - Psoriasis, Plaque Psoriasis | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-06-01 | 2026-03-25 |
| Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa Secukinumab - Hidradenitis Suppurativa (HS) | Phase 4 | Recruiting | Novartis Pharmaceuticals | 36 | 2026-06-01 | 2026-09-09 |
| Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients Secukinumab, Standard of Care (SOC) - Takayasu Arteritis, Large Vessel Vasculitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 52 | 2026-04-01 | 2026-03-27 |
| IL-17 Blockade to Decrease irAEs (REPLAY) Secukinumab Injection - Metastatic Melanoma | Phase 1 | Recruiting | Duke University | 4 | 2026-03-12 | 2026-06-04 |
| Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea Secukinumab - Hidradenitis Suppurativa, Pediatric Plaque Psoriasis | Recruiting | Novartis Pharmaceuticals | 76 | 2025-12-22 | 2026-03-05 | |
| Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers Secukinumab 150mg s.c. - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2025-12-15 | 2026-10-21 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry. Secukinumab - Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA) | Not yet recruiting | Novartis Pharmaceuticals | 100 | 2025-12-01 | 2025-09-24 | |
| Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). Secukinumab - Juvenile Psoriatic Arthritis | Phase 1 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-09-24 | 2026-10-13 |
| Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms Secukinumab, Bimekizumab, Ixekizumab - Psoriatic Arthritis, Depression | Recruiting | NHS Greater Glasgow and Clyde | 50 | 2025-06-02 | 2025-06-19 | |
| Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa Secukinumab - Hidradenitis Suppurativa (HS) | Recruiting | Peking Union Medical College | 50 | 2025-06-01 | 2025-08-07 | |
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy Picankibart, Secukinumab, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 308 | 2025-05-27 | 2026-03-25 |
| Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis Secukinumab - Juvenile Idiopathic Arthritis | Withdrawn | Novartis Pharmaceuticals | 2025-04-30 | 2026-08-07 | ||
| Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. Secukinumab - Ankylosing Spondylitis | Recruiting | Novartis Pharmaceuticals | 70 | 2025-04-02 | 2026-08-18 | |
| Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia Secukinmab - Hidradenitis Suppurativa (HS) | Recruiting | Novartis Pharmaceuticals | 77 | 2025-03-10 | 2025-12-30 | |
| Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab. Secukinumab - Hidradenitis Suppurativa | Active not recruiting | Novartis Pharmaceuticals | 53 | 2025-03-10 | 2026-06-16 | |
| Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis Secukinumab, Adalimumab - Ankylosing Spondylitis | Phase 4 | Not yet recruiting | The Affiliated Hospital Of Guizhou Medical University | 10 | 2025-02-01 | 2025-02-18 |
Showing 20 of 225. Sign in to see all of them.
Psoriasis (63) · Arthritis, Psoriatic (34) · Spondylitis, Ankylosing (22) · Plaque, Amyloid (15) · Hidradenitis Suppurativa (14) · Arthritis, Rheumatoid (11) · Skin Diseases (11) · Axial Spondyloarthritis (10) · Dermatitis (9) · Pruritus (9) · Uveitis (8) · Arthritis, Juvenile (7) · Panuveitis (7) · Uveitis, Intermediate (7) · Uveitis, Posterior (7)
Novartis Pharmaceuticals (148) · Janssen Research & Development, LLC (3) · Taizhou Mabtech Pharmaceutical Co.,Ltd (3) · University of Erlangen-Nürnberg Medical School (3) · Assistance Publique - Hôpitaux de Paris (2) · Bio-Thera Solutions (2) · Icahn School of Medicine at Mount Sinai (2) · Novartis (2) · Peking Union Medical College (2) · Universita di Verona (2) · University Hospital, Ghent (2) · University of California, San Francisco (2) · AbbVie (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Anne Chang (1)
United States (108) · Germany (91) · United Kingdom (56) · Italy (51) · Spain (51) · Canada (48) · Czechia (48) · France (45) · Belgium (44) · Poland (43) · Russia (41) · Hungary (30) · Japan (30) · Israel (29) · Bulgaria (28)
Alexa Kimball, MD MPH (1) · Alexis Ogdie-Beatty, MD (1) · Amy Paller, MD (1) · Anne Chang, MD (1) · April Salama, MD (1) · Chang-Keun Lee, MD (1)
PMID 35305260, PMID 31203228, PMID 37341961, PMID 41965705, PMID 34618347, PMID 27573260, PMID 27576559, PMID 33722947, PMID 34110605, PMID 34795065, PMID 38446397, PMID 20926833, PMID 23290985, PMID 31087226, PMID 32352653, PMID 33227175, PMID 33351179, PMID 33748660, PMID 34773130, PMID 25007392, PMID 26267726, PMID 26699169, PMID 28544533, PMID 30564451, PMID 30972746, PMID 31801620, PMID 33252266, PMID 34870789, PMID 36334236, PMID 36746171, PMID 39101698, PMID 39400109, PMID 39411974, PMID 39425517, PMID 40372667, PMID 40489668, PMID 40839197, PMID 41092316, PMID 22236226, PMID 22595313, PMID 22730366, PMID 23607128, PMID 24035250, PMID 24393602, PMID 24429175, PMID 25243910, PMID 25354738, PMID 25638011, PMID 25881759, PMID 26092291
2015 (11), 2009 (10), 2017 (9), 2016 (6), 2018 (5), 2019 (5), 2023 (5), 2008 (3), 2014 (3)